ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong, S.A.R., China and Macau, S.A.R., China
September 23, 2020Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition. -
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
September 14, 2020Viking Therapeutics announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available thyroid receptor beta (TRβ) agonist in development as a potential treatment for ...
Pharma Sources Insight January 2025
